Prevenar
pneumococcal saccharide conjugated vaccine, adsorbed
Table of contents
Overview
The marketing authorisation for Prevenar has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Prevenar
|
| Agency product number |
EMEA/H/C/000323
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
pneumococcal saccharide conjugated vaccine, adsorbed
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
J07AL02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
23
|
| Date of issue of marketing authorisation valid throughout the European Union |
02/02/2001
|
| Contact address | |
Product information
22/06/2015 Prevenar - EMEA/H/C/000323 - PSUSA/00002452/201408
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
Active immunisation against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.
The use of Prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.